# Pharmaceutical Grade Lactose Market

> 药用级乳糖市场研究报告：按类型（结晶单水乳糖、吸入乳糖、颗粒乳糖和喷雾干燥乳糖）、按应用（片剂制造和胶囊制造）以及按地区（北美、欧洲、亚太和其他地区）-市场预测至2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.22%
- **2024:** $ 1,988.66 Million
- **2025:** $ 2,092.48 Million
- **2035:** $ 3,480.59 Million
- **Key Players:** Lactalis Ingredients (FR), Fonterra Co-operative Group (NZ), Dairy Farmers of America (US), Hilmar Cheese Company (US), Glanbia Nutritionals (IE), Arla Foods Ingredients (DK), Südzucker AG (DE), Murray Goulburn Co-operative Co. Limited (AU), FrieslandCampina (NL)

**Report ID:** MRFR/Pharma/3389-CR · **Pages:** 141 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/pharmaceutical-grade-lactose-market-4816

---

## Market Summary

As per MRFR analysis, the Pharmaceutical Grade Lactose Market Size was estimated at 1988.66 USD Million in 2024. The Pharmaceutical Grade Lactose industry is projected to grow from 2092.48 USD Million in 2025 to 3480.59 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.22% during the forecast period 2025 - 2035.

## Market Drivers

### Rising Demand for Generic Pharmaceuticals

全球药用级乳糖市场行业经历了对仿制药显著增加的需求，这些药物通常将乳糖作为赋形剂。随着越来越多的国家实施促进仿制药使用的政策，市场预计将显著扩展。到2024年，市场预计将达到19.9亿美元，推动这一增长的是医疗服务提供者和患者对仿制药的日益接受。这一趋势可能会持续，预计市场在2025年至2035年间的年均增长率为5.22%，到2035年最终达到34.8亿美元。这些发展表明乳糖在药用应用中的强劲未来。

### Growing Health Consciousness Among Consumers

全球药用级乳糖市场行业受到消费者健康意识提高的影响，导致对乳糖基产品的需求增加。随着个人越来越意识到赋形剂在药物配方中的重要性，乳糖作为一种安全有效成分的偏好上升。这一趋势在健康法规严格的地区尤为明显，在这些地区，药用成分的质量至关重要。市场的增长进一步得益于慢性疾病的日益普遍，迫切需要有效的药物配方来利用乳糖。这种不断发展的消费者行为可能会在未来几年内维持市场的扩张。

### Technological Advancements in Lactose Production

乳糖生产工艺的技术进步对全球药用级乳糖市场行业产生了积极影响。改进的过滤技术和酶促工艺等创新提高了乳糖的纯度和产量，使其更适合药用应用。这些进步不仅降低了生产成本，还确保了符合严格的监管标准。因此，制造商更好地满足对高质量乳糖日益增长的需求。持续的研发投资预计将进一步推动市场，符合到2035年达到34.8亿美元的预期增长轨迹。

### Regulatory Support for Lactose in Pharmaceuticals

对乳糖在药物配方中使用的监管支持增强了全球药用级乳糖市场行业。各类卫生当局认可乳糖作为安全的赋形剂，促进其在药物配方中的应用。这一认可不仅增强了乳糖的可信度，还鼓励制造商在其产品中使用乳糖。随着监管框架的发展以支持药物创新，对高质量乳糖的需求预计将上升。这种监管支持对于维持市场的稳定和增长至关重要，特别是随着行业预计到2035年达到34.8亿美元。

### Expansion of Pharmaceutical Manufacturing in Emerging Markets

新兴市场制药制造的扩展对全球药用级乳糖市场行业产生了显著影响。印度和中国等国的制药部门正在快速增长，推动这一增长的是投资增加和有利的政府政策。这一扩展创造了对赋形剂（包括乳糖）的更高需求，因为制造商寻求提高其产品的质量。市场预计将从2024年的19.9亿美元增长到2035年的34.8亿美元，反映出2025年至2035年间5.22%的强劲年均增长率。这一趋势强调了乳糖在满足蓬勃发展的制药市场需求中的潜力。

## Future Outlook

预计药用级乳糖市场将在2025年至2035年期间以5.22%的年均增长率增长，推动因素是药物配方中的需求增加和乳糖的功能特性。

到2035年，药用级乳糖市场预计将巩固其作为药用辅料的关键参与者的地位。

## Segment Insights

### 按应用：片剂（最大）与粉末（增长最快）

在药用级乳糖市场中，应用细分主要由片剂主导，由于其便利性和在制药行业的广泛使用，片剂占据了显著的市场份额。片剂因其精确的剂量和稳定性而受到青睐，适用于各种配方。紧随其后的是胶囊，而粉末和颗粒虽然市场份额较小，但由于其在专业配方中的应用，正在获得关注。

应用：片剂（主导）与粉末（新兴）

片剂因其多功能性和片剂配方技术的进步，已在药用级乳糖市场中确立了主导地位。它们因制造简便和活性药物成分的稳定释放而受到青睐。相比之下，粉末作为替代品正在迅速崛起，尤其是在复合和定制药物方面。粉末的增长可归因于对个性化医疗的需求增加以及对各种给药方式的需求，包括吸入器和外用药物。这一转变反映了制药配方灵活性更广泛的趋势，以满足不同患者的需求。

### 按最终用途：制药（最大）与营养保健品（增长最快）

在药用级乳糖市场中，最大的细分是制药，占据了显著的份额，因为它在药物配方中作为赋形剂发挥着关键作用。该领域受益于对高质量制药产品的需求不断增长以及遵循严格法规的重要性，这强调了使用药用级材料的重要性。
 
 相反，营养保健品细分正在获得市场份额，被认为是市场中增长最快的领域，受到消费者对健康和保健意识提高以及对功能性食品和膳食补充剂投资增加的推动。药用级乳糖市场的增长趋势显示出制药和营养保健品的强劲轨迹。制药部门受到药物开发持续创新和对个性化医疗日益关注的推动，导致对高性能赋形剂的需求增加。同时，营养保健品细分由于消费者对预防性医疗的倾向增强而经历增长，乳糖被用于各种旨在改善消化健康和整体福祉的补充剂配方中。

制药（主导）与营养保健品（新兴）

制药在药用级乳糖市场中占据主导地位，主要作为片剂和胶囊配方中的重要赋形剂。该细分利用严格的质量标准以确保药物递送系统中的产品有效性和安全性。另一方面，营养保健品作为重要参与者，满足对增强健康和预防健康问题的健康补充剂日益增长的需求。该细分以创新产品开发为特征，其中药用级乳糖因其功能特性而被利用，包括增强营养吸收和消化健康益处。随着消费者倾向于预防性健康解决方案，乳糖在该领域的采用预计将扩大，使其成为未来增长的关键领域。

### 按形式：乳糖单水合物（最大）与无水乳糖（增长最快）

药用级乳糖市场展示了多样化的产品组合，特别是在“形式”细分中，乳糖单水合物因其在制药中的广泛应用而占据最大的市场份额。它增强药物配方的能力，作为赋形剂，使其在竞争对手中占据主导地位。另一方面，无水乳糖虽然与乳糖单水合物相比市场份额较小，但正在迅速获得关注，显示出在需求较低水分含量的应用中采用的良好增长。

乳糖单水合物（主导）与无水乳糖（新兴）

乳糖单水合物以其多功能性和作为片剂配方中的填充剂和粘合剂的有效性而闻名，使其成为制药行业的首选。其稳定的特性有助于延长保质期和提高配方的稳定性，这对药物的有效性至关重要。相反，无水乳糖因其最低的水分含量，正在成为专业制药应用中的关键参与者。其快速增长可归因于对药物配方中高性能赋形剂需求的增加，使其成为向更先进制药技术过渡的关键驱动力。

### 按来源：牛奶（最大）与合成生产（增长最快）

在药用级乳糖市场中，来源细分主要由牛奶主导，因其广泛的可用性和成本效益而占据最大份额。人乳也对市场有所贡献，但由于供应有限和相关成本较高，其份额显著较小。合成生产虽然目前在市场中占据较小部分，但随着技术的进步，正逐渐成为乳糖生产的可行替代方案。

牛奶（主导）与合成生产（新兴）

牛奶仍然是药用级乳糖市场中的主导来源，因其高产量和成熟的供应链基础设施而受到青睐。其一致性和质量对制药应用至关重要。另一方面，合成生产作为一种创新方法正在崛起，以满足对乳糖日益增长的需求，因为其具有可扩展性和减少对动物来源的依赖。该细分特别吸引那些寻找符合特定纯度标准的乳糖的制造商，而无需担心与动物产品相关的问题。合成选项的增长表明制药行业向可持续性和效率更广泛的趋势。

### 按纯度水平：高纯度（最大）与低纯度（增长最快）

在药用级乳糖市场中，按纯度水平的市场份额分布显示高纯度为主导细分，吸引需要卓越质量的制造商进行配方。低纯度乳糖虽然市场份额较小，但越来越多地被寻求成本效益解决方案的生产商所采用，这些应用不需要严格的纯度标准。这一趋势表明制药公司针对其产品组合特定细分市场所采取的差异化策略。

高纯度（主导）与低纯度（新兴）

高纯度药用级乳糖以其卓越的质量和最小的杂质为特征，使其在制药行业的关键应用中至关重要，包括片剂配方和可吸入产品中的赋形剂。由于严格的监管要求推动对高等级材料的需求，其市场地位稳固。相反，低纯度乳糖作为对需要较低纯度标准的应用的替代品正在迅速崛起，吸引关注成本效率的制造商。虽然它不适合高端制药，但它有效服务于非关键应用的增长领域，平衡质量和可负担性。

## Regional Market Share Analysis

### North America : Market Leader in Lactose

North America is poised to maintain its leadership in the Pharmaceutical Grade Lactose market, holding a significant market share of 994.33 million. The region's growth is driven by increasing demand for lactose in pharmaceuticals, particularly in the production of excipients and drug formulations. Regulatory support and stringent quality standards further enhance market dynamics, fostering innovation and investment in lactose production facilities. The United States stands out as the leading country, with major players like Dairy Farmers of America and Hilmar Cheese Company driving competition. The presence of established companies ensures a robust supply chain and product availability. Additionally, the region benefits from advanced research and development capabilities, positioning it as a hub for lactose innovation and application in the pharmaceutical sector.

### Europe : Regulatory Framework and Growth

Europe's Pharmaceutical Grade Lactose market is valued at 600.0 million, reflecting a steady growth trajectory. The region's expansion is fueled by increasing healthcare expenditures and a rising demand for lactose-based excipients in drug formulations. Regulatory frameworks, such as the European Medicines Agency guidelines, play a crucial role in ensuring product quality and safety, thereby boosting market confidence and investment. Leading countries like Germany, France, and the Netherlands are at the forefront of this market, with key players such as FrieslandCampina and Südzucker AG contributing significantly. The competitive landscape is characterized by innovation and collaboration among manufacturers, ensuring a diverse range of lactose products tailored to meet specific pharmaceutical needs. This dynamic environment fosters continuous improvement and adaptation to market demands.

### Asia-Pacific : Emerging Market Potential

The Asia-Pacific region, with a market size of 300.0 million, is emerging as a significant player in the Pharmaceutical Grade Lactose market. The growth is driven by increasing healthcare access, rising pharmaceutical manufacturing, and a growing awareness of lactose's benefits in drug formulations. Countries like China and India are witnessing rapid advancements in their pharmaceutical sectors, supported by favorable government policies and investments in healthcare infrastructure. China leads the market in the region, with a burgeoning pharmaceutical industry that demands high-quality lactose for various applications. The competitive landscape includes both local and international players, fostering a dynamic environment for innovation. Companies are increasingly focusing on expanding their product offerings and enhancing production capabilities to meet the growing demand for lactose in pharmaceuticals, positioning the region for substantial growth in the coming years.

### Middle East and Africa : Developing Market Landscape

The Middle East and Africa region, with a market size of 94.33 million, is gradually developing its Pharmaceutical Grade Lactose market. The growth is primarily driven by increasing healthcare investments and a rising demand for lactose in pharmaceutical applications. Regulatory initiatives aimed at improving healthcare standards are also contributing to market expansion, creating opportunities for lactose manufacturers to enter this emerging market. Countries like South Africa and the UAE are leading the way in pharmaceutical advancements, with a growing number of local manufacturers entering the lactose market. The competitive landscape is characterized by a mix of established players and new entrants, fostering innovation and collaboration. As the region continues to develop its pharmaceutical capabilities, the demand for high-quality lactose is expected to rise, paving the way for future growth.

## Competitive Benchmarking

The Pharmaceutical Grade Lactose Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on sustainability. Key players such as Lactalis Ingredients (FR), Fonterra Co-operative Group (NZ), and Glanbia Nutritionals (IE) are actively pursuing strategies that enhance their market positioning. Lactalis Ingredients (FR) emphasizes product innovation and quality assurance, which appears to resonate well with the growing demand for high-purity lactose in pharmaceutical applications. Meanwhile, Fonterra Co-operative Group (NZ) is focusing on expanding its global footprint through strategic partnerships, thereby enhancing its supply chain capabilities and market reach. Glanbia Nutritionals (IE) is also investing in digital transformation initiatives to optimize its operations and improve customer engagement, indicating a collective shift towards leveraging technology in the competitive environment. The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure is moderately fragmented, with several key players exerting influence over pricing and product offerings. This fragmentation allows for a diverse range of products, catering to various customer needs, while also fostering competition among established and emerging players. In November 2025, Lactalis Ingredients (FR) announced the launch of a new line of lactose products specifically designed for the pharmaceutical sector, which is expected to enhance its competitive edge. This strategic move not only diversifies its product portfolio but also aligns with the increasing demand for lactose in drug formulation, thereby positioning the company favorably in a growing market segment. Furthermore, in October 2025, Fonterra Co-operative Group (NZ) entered into a strategic alliance with a leading pharmaceutical company to co-develop lactose-based excipients, which could potentially streamline the development process for new drug formulations and enhance Fonterra's market presence. In September 2025, Glanbia Nutritionals (IE) expanded its production capacity for pharmaceutical-grade lactose by investing in state-of-the-art manufacturing technology. This investment is likely to improve production efficiency and product quality, thereby meeting the stringent requirements of the pharmaceutical industry. Such strategic actions reflect a broader trend among key players to enhance operational capabilities and respond to the evolving needs of the market. As of December 2025, current competitive trends in the Pharmaceutical Grade Lactose Market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence (AI) into production processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. The competitive differentiation is expected to evolve from traditional price-based competition towards a model that prioritizes innovation, technological advancement, and supply chain reliability. This shift suggests that companies that can effectively leverage these trends will likely secure a more robust position in the market.

## Recent News & Developments

_**July 2022: **__DFE Pharma, a leader in pharma- and nutraceutical excipient solutions, announces the expansion of its dry powder inhalation (DPI) portfolio with the launch of Lactohale 400. Adding Lactohale 400 further enhances the completeness of DFE Pharma's portfolio of inhalation grade lactose._

 _**July 2022: **__Danone launched the first ever Dairy and Plants Blend baby formula in response to parents' desire for vegetarian and flexitarian options for their babies. Plant-based consumption is growing substantially, with over one-third [37%] of EU consumers choosing a vegan, vegetarian or flexitarian diet, and almost 70% [69%] of parents now preferring their children to eat more plant-based foods. Until now, there have been rare options for parents if they choose to move on from breastmilk and want to create healthier, more plant-based food choices and good for the planet._

## Report Scope

| MARKET SIZE 2024 | 1988.66(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2092.48(USD Million) |
| MARKET SIZE 2035 | 3480.59(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.22% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Lactalis Ingredients (FR), Fonterra Co-operative Group (NZ), Dairy Farmers of America (US), Hilmar Cheese Company (US), Glanbia Nutritionals (IE), Arla Foods Ingredients (DK), Südzucker AG (DE), Murray Goulburn Co-operative Co. Limited (AU), FrieslandCampina (NL) |
| Segments Covered | Application, End Use, Form, Source, Purity Level |
| Key Market Opportunities | Growing demand for lactose-based excipients in drug formulation enhances opportunities in the Pharmaceutical Grade Lactose Market. |
| Key Market Dynamics | Rising demand for lactose in drug formulation drives innovation and competition among pharmaceutical manufacturers. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current market valuation of the Pharmaceutical Grade Lactose Market?**
A: As of 2024, the market valuation was 1988.66 USD Million.

**Q: What is the projected market size for the Pharmaceutical Grade Lactose Market by 2035?**
A: The market is projected to reach 3480.59 USD Million by 2035.

**Q: What is the expected CAGR for the Pharmaceutical Grade Lactose Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period is 5.22%.

**Q: Which companies are considered key players in the Pharmaceutical Grade Lactose Market?**
A: Key players include Lactalis Ingredients, Fonterra Co-operative Group, and Dairy Farmers of America, among others.

**Q: What are the primary applications of pharmaceutical grade lactose?**
A: The primary applications include tablets, capsules, powders, and granules, with tablets valued at 794.0 USD Million in 2024.

**Q: How does the Pharmaceutical Grade Lactose Market segment by end use?**
A: The market segments by end use include pharmaceuticals, nutraceuticals, cosmetics, and the food industry, with pharmaceuticals valued at 1000.0 USD Million in 2024.

**Q: What forms of lactose are available in the Pharmaceutical Grade Lactose Market?**
A: Available forms include anhydrous lactose, hydrate lactose, and lactose monohydrate, with lactose monohydrate valued at 988.66 USD Million in 2024.

**Q: What sources of lactose are utilized in the Pharmaceutical Grade Lactose Market?**
A: Sources include bovine milk, human milk, and synthetic production, with bovine milk valued at 794.66 USD Million in 2024.

**Q: How is the Pharmaceutical Grade Lactose Market categorized by purity level?**
A: The market is categorized by purity level into low, medium, and high purity, with high purity valued at 1188.66 USD Million in 2024.

**Q: What trends are anticipated in the Pharmaceutical Grade Lactose Market by 2035?**
A: Trends suggest continued growth, with the market likely expanding to 3480.59 USD Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/pharmaceutical-grade-lactose-market-4816*